

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 28, 2002, 11:25:22 ; Search time 13.07 Seconds  
(without alignments)  
717.630 Million cell updates/sec

Title: US-09-810-936-304

Perfect score: 2064

Sequence: 1 MVVEVDSMPAASSVKPFGL.....MLKISSNSNPENVSRTNK 384

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued Patents AA.\*
- 1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pap.\*
  - 2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pap.\*
  - 3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pap.\*
  - 4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pap.\*
  - 5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pap.\*
  - 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2064	100.0	1719	4	US-09-439-313-378
2	2024	98.1	656	4	Sequence 378, App
3	2024	98.1	671	4	Sequence 379, App
4	1314	63.7	292	4	Sequence 380, App
5	1136	55.0	329	4	Sequence 532, App
6	623	30.2	148	4	Sequence 376, App
7	231	11.2	1423	4	Sequence 377, App
8	230.5	11.2	843	2	Sequence 10, App
9	228.5	11.1	352	3	Sequence 3, Appli
10	228.5	11.1	1745	2	Sequence 139, App
11	228.5	11.1	1745	2	Sequence 33, Appl
12	228.5	11.1	1745	3	Sequence 33, Appl
13	228.5	11.1	1839	2	Sequence 33, Appl
14	226	10.9	949	4	Sequence 4, Appli
15	226	10.9	1327	4	Sequence 10, Appl
16	225	10.9	1088	4	Sequence 2, Appli
17	224	10.9	673	4	Sequence 2, Appli
18	221.5	10.7	787	4	Sequence 8, Appli
19	209.5	10.2	303	2	Sequence 334, App
20	209.5	10.2	303	2	Sequence 33, Appl
21	209.5	10.2	303	3	Sequence 23, Appl
22	209.5	10.2	303	3	Sequence 23, Appl
23	209.5	10.2	687	2	Sequence 21, Appl
24	209	10.1	688	2	Sequence 21, Appl
25	209	10.1	688	4	Sequence 23, Appl
26	206	10.0	752	1	Sequence 23, Appl
27	206	10.0	752	1	Sequence 2, Appli

28	206	10.0	752	2	US-08-735-716-2	Sequence 2, Appli
29	206	10.0	752	2	US-08-555-568B-2	Sequence 2, Appli
30	206	10.0	752	4	US-09-519-223-2	Sequence 2, Appli
31	206	10.0	752	5	PCT-US95-08069-2	Sequence 2, Appli
32	205.5	10.0	422	2	US-08-484-575A-6	Sequence 6, Appli
33	205.5	10.0	422	3	US-08-477-459-6	Sequence 6, Appli
34	205.5	10.0	422	3	US-08-479-869-6	Sequence 6, Appli
35	205.5	10.0	422	4	US-08-486-414-6	Sequence 6, Appli
36	205.5	10.0	422	5	PCT-US94-01826A-6	Sequence 6, Appli
37	205.5	10.0	422	5	PCT-US94-02252A-6	Sequence 6, Appli
38	203.5	9.9	718	4	US-08-973-005A-12	Sequence 12, Appl
39	203	9.8	348	2	US-09-031-485-28	Sequence 28, Appl
40	203	9.8	348	2	US-08-847-429A-28	Sequence 28, Appl
41	203	9.8	348	3	US-09-065-474-28	Sequence 28, Appl
42	201.5	9.8	302	2	US-09-031-485-38	Sequence 38, Appl
43	201.5	9.8	302	2	US-08-847-429A-38	Sequence 38, Appl
44	201.5	9.8	302	3	US-09-065-474-38	Sequence 38, Appl
45	200	9.7	394	2	US-08-555-568B-17	Sequence 17, Appl

#### ALIGNMENTS

RESULT 1  
US-09-439-313-378  
; Sequence 378, Application US/09439313  
; Patent No. 6329505  
; GENERAL INFORMATION:  
; APPLICANT: Xu, Jiangchun  
; APPLICANT: Dillon, Davin C.  
; APPLICANT: Mitcham, Jennifer L.  
; APPLICANT: Harlocker, Susan Louise  
; APPLICANT: Jiang Yuqui  
; APPLICANT: Reed, Steven G.  
; APPLICANT: Kalos, Michael  
; APPLICANT: Fanger, Gary  
; APPLICANT: Retter, Mark  
; APPLICANT: Solk, John  
; APPLICANT: Day, Craig  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND  
; TITLE OF INVENTION: DIAGNOSIS OF PROSTATE CANCER  
; FILE REFERENCE: 210121.427C9  
; CURRENT FILING DATE: 1999-11-12  
; NUMBER OF SEQ ID NOS: 575  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 378  
; LENGTH: 1719  
; TYPE: PRT  
; ORGANISM: Homo sapien  
US-09-439-313-378

Query Match 100.0%; Score 2064; DB 4; Length 1719;  
Best Local Similarity 100.0%; Pred. No. 2e+204;  
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MVVEVDSMPAASSVKPFGLRSGKSNVGTSGDHHDSAMKTLRSK	60
Db	1	MVVEVDSMPAASSVKPFGLRSGKSNVGTSGDHHDSAMKTLRSK	60
QY	61	MGKWCRCPCCRGSGKSNVGTSGDHHDSAMKTLRNMKGKWCCHCPCCRGSGSKVGAW	120
Db	61	MGKWCRCPCCRGSGKSNVGTSGDHHDSAMKTLRNMKGKWCCHCPCCRGSGSKVGAW	120
QY	121	GDYDVSFAFMEPRYHVHVRGDLKLHRAAWKGVPRKDLIVMLRDTDVNKKDKQKRTALHIA	180
Db	121	GDYDVSFAFMEPRYHVHVRGDLKLHRAAWKGVPRKDLIVMLRDTDVNKKDKQKRTALHIA	180
QY	181	SANGNSEVVKLLLDRCQLNVLDNKKRTALIKAVQCEDECALMLEHGTDPNIPDEYGN	240
Db	181	SANGNSEVVKLLLDRCQLNVLDNKKRTALIKAVQCEDECALMLEHGTDPNIPDEYGN	240



```
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: Harlocker, Susan Louise
; APPLICANT: Jiang Yuqui
; APPLICANT: Reed, Steven G.
; APPLICANT: Kalos, Michael
; APPLICANT: Fanger, Gary
; APPLICANT: Retter, Mark
; APPLICANT: Solk, John
; APPLICANT: Day, Craig
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; FILE OF INVENTION: DIAGNOSIS OF PROSTATE CANCER
; FILE REFERENCE: 210121.427C9
; CURRENT APPLICATION NUMBER: US/09/439,313
; CURRENT FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 575
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 532
; LENGTH: 292
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-439-313-532

Query Match      63.7%; Score 1314; DB 4; Length 292;
Best Local Similarity 92.8%; Pred. No. 6.3e-128;
Matches 245; Conservative 10; Mismatches 9; Indels 0; Gaps 0;

QY 73 RSGSKSNVGASGDHSDSANKTIRNMKGWCCHPCPCRGSKSKVGAWGDDYDDSAFMEPR 132
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 15 RSGSKSNVGTSGDNDSSVKTLGSKRCKWCCHPCPCRGSKSKNVVWAGDYDDSAFMDPR 74
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 133 YHVRGEDLDKHLRAAWGKVPKDLIVMLRDTDNKKDKQKRTALHLASANGSEVVKLL 192
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 75 YHVRGEDLDKHLRAAWGKVPKDLIVMLRDTDNKKDKQKRTALHLASANGSEVVKLV 134
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 193 LDRRCQLNVLDNKKRTALIKAVQCEDECALMLLEHGTDPNIPDEYGNITLHYAIYNEDK 252
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 135 LDRRCQLNVLDNKKRTALTAVQCEDECALMLLEHGTDPNIPDEYGNITLHYAIYNEDK 194
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 253 LMAKALLYGADIESKNKHGLTPLLGVHEQKQVWVFLIKKANLALDRYGRRTALILA 312
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 195 LMAKALLYGADIESKNKHGLTPLLGLIHEQKQVWVFLIKKANLALDRYGRRTALILA 254
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 313 VCCGSASIVSLLLEQNIDVSSQDL 336
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 255 VCCGSASIVSPLLEQNVDVSSQDL 278
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 5
US-09-439-313-376
; Sequence 376, Application US/09439313
; Patent No. 6329505
; GENERAL INFORMATION:
; APPLICANT: Xu, Jiangchun
; APPLICANT: Dillon, Davin C.
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: Harlocker, Susan Louise
; APPLICANT: Jiang Yuqui
; APPLICANT: Reed, Steven G.
; APPLICANT: Kalos, Michael
; APPLICANT: Fanger, Gary
; APPLICANT: Retter, Mark
; APPLICANT: Solk, John
; APPLICANT: Day, Craig
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; FILE OF INVENTION: DIAGNOSIS OF PROSTATE CANCER
; FILE REFERENCE: 210121.427C9
; CURRENT APPLICATION NUMBER: US/09/439,313
; CURRENT FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 575
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 377
; LENGTH: 148
; TYPE: PRT
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(148)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-439-313-377
```

```
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-439-313-376

Query Match      55.0%; Score 1136; DB 4; Length 329;
Best Local Similarity 93.9%; Pred. No. 2e-109;
Matches 216; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

QY 107 PCCRGSCKSKVGAWGDDYDDSAFMEPRYHVRGEDLDKHLRAAWGKVPKDLIVMLRDTDV 166
|:||||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 86 PLLQSGSKSNVWAGWDDYDDSAFMDPRYHVRGEDLDKHLRAAWGKVPKDLIVMLRDTDV 145
|:||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 167 NKDKQKRTALHLASANGSEVVKLLLDRRCQLNVLDNKKRTALIKAVQCEDECALMLL 226
|:||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 146 NKDKQKRTALHLASANGSEVVKLVLDRCQLNVLDNKKRTALTAVQCEDECALMLL 205
|:||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 227 EHGTDPNIPDEYGNITLHYAIYNEDKLMAKALLYGADIESKNKHGLTPLLGVHEQKQ 286
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 206 EHGTDPNIPDEYGNITLHYAVYNEDKLMAKALLYGADIESKNKHGLTPLLGIHEQKQ 265
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 287 VVKFLIKKANLALDRYGRRTALILAVCCGSASIVSLLLEQNIDVSSQDL 336
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 266 VVKFLIKKANLALDRYGRRTALILAVCCGSASIVSPLLEQNVDVSSQDL 315
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 6
US-09-439-313-377
; Sequence 377, Application US/09439313
; Patent No. 6329505
; GENERAL INFORMATION:
; APPLICANT: Xu, Jiangchun
; APPLICANT: Dillon, Davin C.
; APPLICANT: Mitcham, Jennifer L.
; APPLICANT: Harlocker, Susan Louise
; APPLICANT: Jiang Yuqui
; APPLICANT: Reed, Steven G.
; APPLICANT: Kalos, Michael
; APPLICANT: Fanger, Gary
; APPLICANT: Retter, Mark
; APPLICANT: Solk, John
; APPLICANT: Day, Craig
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; FILE OF INVENTION: DIAGNOSIS OF PROSTATE CANCER
; FILE REFERENCE: 210121.427C9
; CURRENT APPLICATION NUMBER: US/09/439,313
; CURRENT FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 575
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 377
; LENGTH: 148
; TYPE: PRT
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)...(148)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-439-313-377

Query Match      30.2%; Score 623; DB 4; Length 148;
Best Local Similarity 96.7%; Pred. No. 7.5e-57;
Matches 119; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 148 WVGKVPKDLIVMLRDTDVNKKDKQKRTALHLASANGSEVVKLLLDRRCQLNVLDNKKR 207
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 25 WVGKVPKDLIVMLRDTDVNKKDKQKRTALHLASANGSEVVKLVLDRCQLNVLDNKKR 84
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 208 TALIKAVQCEDECALMLLEHGTDPNIPDEYGNITLHYAIYNEDKLMAKALLYGADIES 267
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 85 TALXKAVQCEDECALMLLEHGTDPNIPDEYGNITLHYAXYNEDKLMAKALLYGADIES 144
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 268 KNK 270
```

```

Db      145 KMK 147

|||||
RESULT 7
US-08-810-712-10
; Sequence 10, Application US/08810712G
; Patent No. 6160106
; GENERAL INFORMATION:
; APPLICANT: Yeda Research and Development Co. LTD
; TITLE OF INVENTION: Tumor Suppressor Genes, Proteins Encoded Thereby and
; TITLE OF INVENTION: Use of said Genes and Proteins
; FILE REFERENCE: sequencelist
; CURRENT APPLICATION NUMBER: US/08/810,712G
; CURRENT FILING DATE: 1997-03-03
; EARLIER APPLICATION NUMBER: PCT/US94/11598
; EARLIER FILING DATE: 1994-10-12
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 1423
; TYPE: PRT
; ORGANISM: Homo sapiens
US-08-810-712-10

```

[illegible]

```

RESULT      8
US-09-172-977-3
; Sequence 3, Application US/09172977
; Patent No. 5989863
; GENERAL INFORMATION:
; APPLICANT: Tang, Y. Tom
; APPLICANT: Guegler, Karl J.
; APPLICANT: Corley, Neil C.
; APPLICANT: Yue, Henry
; TITLE OF INVENTION: HUMAN ANKYRIN FAMILY PROTEIN
; FILE REFERENCE: PF-0615 US
; CURRENT APPLICATION NUMBER: US/09/172,977
; CURRENT FILING DATE: 1998-10-14
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PERL Program
; SEQ ID NO 3
; LENGTH: 843
; TYPE: PRT
; ORGANISM: Rattus norvegicus
; FEATURE: -
; OTHER INFORMATION: g1841966
US-09-172-977-3

```

Query Match	11.2%;	Score 230.5;	DB 2;	Length 843;
Best Local Similarity	28.7%;	Pred. No. 3.7e-15;		

!

	Matches	72;	Conservative	39;	Mismatches	101;	Indels	39;	Gaps	4.
QY	143	LHRAAWGKYPKDLIYLRLD	TDV--NKDKQKRTALHLASANGSENVVKKLLDRRCOLN	200						
		:  :	:  :	:	:	:  :	:			
Db	499	LHISAREGV---	DVASVLLEAGAAHSLATKGFTPLHVAAYGSLDVAKILLQRRAAA	555						
QY	201	VLNKKRTALIKAVCOEDECA	LMLEHGTDPTNPDEYGNITTLHYAIYNEDKLMAKALLL	260						
		:  :	:	:	:  :	:	:  :			
Db	556	SAGKNGLTPLFHAHYDNQKV	ALLLEKGSAPHATAKNGYTPLHIAAKKNOMQIASTLLN	615						
QY	261	YGADIESKNHGLTPPLLGGV	HGEKQQVVVKFLIKKANL-----	298						
		:  :	:	:	:  :	:	:  :			
Db	616	YGAETNTVTQGVTPLHLASO	EHTDMVTIVLEKGANIHMSKSLTSLHLAEEEDKVN	675						
QY	299	-----NALDRYGR	TALILAVCCGSASIYLSLLEQNIDVSSQDLSGT-AREYAV	346						
		:  :	:	:	:  :	:	:  :			
Db	676	ADILTKHGADQDAYTKLGYP	LIIVACHYGNVKNVNFLLKQGANVNAKTNGYTPLHQAAQ	735						
QY	347	SSHHVTCQLL	357							
Db	736	QGHTHIINVL	746							
	RESULT	9								
	US-09-065-474-139									
	; Sequence 139, Application US/09065474									
	; Patent No. 6063599									
	; GENERAL INFORMATION:									
	; APPLICANT: Tang, Liang									
	; APPLICANT: Blehm, E. Scot									
	; TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN									
	; TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND									
	; TITLE OF INVENTION: USES THEREOF									
	; NUMBER OF SEQUENCES: 171									
	; CORRESPONDENCE ADDRESS:									
	; ADDRESSEE: Carol Talkington Verser, Ph.D.									
	; ADDRESSEE: Heska Corporation									
	; STREET: 1825 Sharp Point Drive									
	; CITY: Fort Collins									
	; STATE: Colorado									
	; COUNTRY: USA									
	; ZIP: 80525									
	; COMPUTER READABLE FORM:									
	; MEDIUM TYPE: Floppy disk									
	; COMPUTER: IBM PC compatible									
	; OPERATING SYSTEM: Windows 95									
	; SOFTWARE: WordPerfect for Windows, Version 7.0									
	; CURRENT APPLICATION DATA:									
	; APPLICATION NUMBER: US/09/065,474									
	; FILING DATE: 24-APR-1998									
	; CLASSIFICATION:									
	; ATTORNEY/AGENT INFORMATION:									
	; NAME: Verser, Carol Talkington									
	; REGISTRATION NUMBER: 37,459									
	; REFERENCE/DOCKET NUMBER: HW-5-C1									
	; TELECOMMUNICATION INFORMATION:									
	; TELEPHONE: 970/493-7272									
	; TELEFAX: 970/484-9505									
	; INFORMATION FOR SEQ ID NO: 139:									
	; SEQUENCE CHARACTERISTICS:									
	; LENGTH: 352 amino acids									
	; TYPE: amino acid									
	; TOPOLOGY: linear									
	; MOLECULE TYPE: Protein									
	; US-09-065-474-139									

```

Query Match      11.1%; Score 228.5; DB 3; Length 352;
Best Local Similarity 29.8%; pred. No. 1.7e-15;
Matches 67; Conservative 45; Mismatches 106; Indels 7; Gaps 4;
Qy 135 VRGEDLDKLHRAAWGKVPKRLD-VMLRD-TDVNKKQKQKTAHLHLSANGNSEVVKLL 192
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||

```

Db 9 VRGE--TPLHLAA---RANQTDIVRLVRNGAQQVDAARAELQTPHLHTASRLGNTDIVILL 63

QY 193 LDRRCQLNVLDNKKRTALIKAVQCOEDCALMLLEHGTDPNIPDEYNTTLHVAIYNEDK 252

Db 64 LQANASPNATRDLYTPHLHAAKEQOEVAAILMDHGTDKTLTKKGFTPLHLAAKYGNL 123

QY 253 LMAKALLYGADIESKNKHGTLPLLLGVHEQOQVVKFLIKKANLNALDRYGR TALILA 312

Db 124 PVAKSLLERGTVDIEGKNQVTPHLVAAHYNNNDKVALLLLENGASAAHAAKNGYTPHLHIA 183

QY 313 VCCGSASIVSLLLEQNIDVSSQDLSGGTAREYAVSSHHHVICQLL 357

Db 184 AKKNQMDIATSLLLHYKANANAESKAGFTPLHLAAQEGHREMAALL 228

RESULT 10

US-09-031-485-33

; Sequence 33, Application US/09031485

; Patent No. 5824306

; GENERAL INFORMATION:

; APPLICANT: Tang, Liang

; APPLICANT: Blehm, E. Scot

; TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN

; TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND

; TITLE OF INVENTION: USES THEREOF

; NUMBER OF SEQUENCES: 85

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Carol Talkington Verser, Ph.D.

; ADDRESSEE: Heska Corporation

; STREET: 1825 Sharp Point Drive

; CITY: Fort Collins

; STATE: Colorado

; COUNTRY: USA

; ZIP: 80525

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: Windows 95

; SOFTWARE: WordPerfect for Windows, Version 7.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/031,485

; FILING DATE:

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/847,429

; FILING DATE: 24-APR-1997

; ATTORNEY/AGENT INFORMATION:

; NAME: Verser, Carol Talkington

; REGISTRATION NUMBER: 37,459

; REFERENCE/DOCKET NUMBER: HW-5

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 970/493-7272

; TELEFAX: 970/484-9505

; INFORMATION FOR SEQ ID NO: 33:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 1745 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-09-031-485-33

Query Match 11.1%; Score 228.5; DB 2; Length 1745;

Best Local Similarity 29.8%; Pred. No. 1.7e-14;

Matches 67; Conservative 45; Mismatches 106; Indels 7; Gaps 4;

QY 135 VRGEDLDKLHRAAWGKVPKDLI-VMLRD-TDVNKKDKOKRTALHLASANGSEVVKLL 192

Db 444 VRGE--TPLHLAA---RANQTDIVRLVRNGAQQVDAARAELQTPHLHTASRLGNTDIVILL 498

QY 193 LDRRCQLNVLDNKKRTALIKAVQCOEDCALMLLEHGTDPNIPDEYNTTLHVAIYNEDK 252

Db 499 LQANASPNATRDLYTPHLHAAKEQOEVAAILMDHGTDKTLTKKGFTPLHLAAKYGNL 558

QY 253 LMAKALLYGADIESKNKHGTLPLLLGVHEQOQVVKFLIKKANLNALDRYGR TALILA 312

Db 559 PVAKSLLERGTVDIEGKNQVTPHLVAAHYNNNDKVALLLLENGASAAHAAKNGYTPHLHIA 618

QY 313 VCCGSASIVSLLLEQNIDVSSQDLSGGTAREYAVSSHHHVICQLL 357

Db 619 AKKNQMDIATSLLLHYKANANAESKAGFTPLHLAAQEGHREMAALL 663

RESULT 11

US-08-847-429A-33

; Sequence 33, Application US/08847429A

; Patent No. 5827692

; GENERAL INFORMATION:

; APPLICANT: Tang, Liang

; APPLICANT: Blehm, E. Scot

; TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN

; TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND

; TITLE OF INVENTION: USES THEREOF

; NUMBER OF SEQUENCES: 85

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Carol Talkington Verser, Ph.D.

; ADDRESSEE: Heska Corporation

; STREET: 1825 Sharp Point Drive

; CITY: Fort Collins

; STATE: Colorado

; COUNTRY: USA

; ZIP: 80525

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: Windows 95

; SOFTWARE: WordPerfect for Windows, Version 7.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/847,429A

; FILING DATE: 24-APR-1997

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Verser, Carol Talkington

; REGISTRATION NUMBER: 37,459

; REFERENCE/DOCKET NUMBER: HW-5

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 970/493-7272

; TELEFAX: 970/484-9505

; INFORMATION FOR SEQ ID NO: 33:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 1745 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

US-08-847-429A-33

Query Match 11.1%; Score 228.5; DB 2; Length 1745;

Best Local Similarity 29.8%; Pred. No. 1.7e-14;

Matches 67; Conservative 45; Mismatches 106; Indels 7; Gaps 4;

QY 135 VRGEDLDKLHRAAWGKVPKDLI-VMLRD-TDVNKKDKOKRTALHLASANGSEVVKLL 192

Db 444 VRGE--TPLHLAA---RANQTDIVRLVRNGAQQVDAARAELQTPHLHTASRLGNTDIVILL 498

QY 193 LDRRCQLNVLDNKKRTALIKAVQCOEDCALMLLEHGTDPNIPDEYNTTLHVAIYNEDK 252

Db 499 LQANASPNATRDLYTPHLHAAKEQOEVAAILMDHGTDKTLTKKGFTPLHLAAKYGNL 558

QY 253 LMAKALLYGADIESKNKHGTLPLLLGVHEQOQVVKFLIKKANLNALDRYGR TALILA 312

Db 559 PVAKSLLERGTVDIEGKNQVTPHLVAAHYNNNDKVALLLLENGASAAHAAKNGYTPHLHIA 618

QY 313 VCCGSASIVSLLLEQNIDVSSQDLSGGTAREYAVSSHHHVICQLL 357

Db 619 AKKNQMDIATSLLLHYKANANAESKAGFTPLHLAAQEGHREMAALL 663

## RESULT 12

US-09-065-474-33  
; Sequence 33, Application US/09065474  
; Patent No. 6063599  
; GENERAL INFORMATION:  
; APPLICANT: Tang, Liang  
; TITLE OF INVENTION: DIROFILARIA AND BRUGIA ANKYRIN  
; TITLE OF INVENTION: PROTEINS, NUCLEIC ACID MOLECULES, AND  
; TITLE OF INVENTION: USES THEREOF  
; NUMBER OF SEQUENCES: 171  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Carol Talkington Verser, Ph.D.  
; ADDRESSEE: Heska Corporation  
; STREET: 1825 Sharp Point Drive  
; CITY: Fort Collins  
; STATE: Colorado  
; COUNTRY: USA  
; ZIP: 80525  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: Windows 95  
; SOFTWARE: WordPerfect for Windows, Version 7.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/065,474  
; FILING DATE: 24-APR-1998  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Verser, Carol Talkington  
; REGISTRATION NUMBER: 37,459  
; REFERENCE/DOCKET NUMBER: HW-5-C1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 970/493-7272  
; TELEFAX: 970/484-9505  
; INFORMATION FOR SEQ ID NO: 33:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1745 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-09-065-474-33

Query Match 11.1%; Score 228.5; DB 3; Length 1745;  
Best Local Similarity 29.8%; Pred. No. 1.7e-14;  
Matches 67; Conservative 45; Mismatches 106; Indels 7; Gaps 4;  
QY 135 VRGDLKLRAMWGKVPKRDLI-VMLRD-TDVNKKDKKRTALHLASANGNSEVVKLL 192  
DB 444 VRGE--TPLHLAA---RANQTDIVRVLRGAQVDAARELQTPHLIASRLGNTDIVILL 498  
QY 193 LDRRCQLNVLDNKKRTALIKAVQCEDECALMLLEHGTDPNIPDEYGNNTLHYAIYNEDK 252  
DB 499 LQANASPNAPFDLYPLHIAAKEGEVEAAILMDHGTDTILTTLTKGFTPLHLAAKYGNL 558  
QY 253 LMAKALLYGADIESKNKHGTLPTLLGVHEQKQOVVKFLIKKANLNALDRYGRITALILA 312  
DB 559 PVAKSILLERGTVPDTEGKNQVTPLRVAHYNNNDKVALLEENGASAAHAAKNGYTPHLIA 618  
QY 313 VCCGSASIVSLLEQNIIDVSSQDLSGGOTAREYAVSSHVVICOLL 357  
DB 619 AKKNQMDIATSLHYKANANAESKAGFTPLHLAAQEGHREMAALL 663

## RESULT 13

US-09-172-977-4  
; Sequence 4, Application US/09172977  
; Patent No. 5989863  
; GENERAL INFORMATION:  
; APPLICANT: Tang, Y. Tom

; APPLICANT: Guegler, Karl J.  
; APPLICANT: Corley, Neil C.  
; APPLICANT: Yue, Henry  
; TITLE OF INVENTION: HUMAN ANKYRIN FAMILY PROTEIN  
; FILE REFERENCE: PF-0615 US  
; CURRENT APPLICATION NUMBER: US/09/172,977  
; CURRENT FILING DATE: 1998-10-14  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PERL Program  
; SEQ ID NO 4  
; LENGTH: 1839  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE: -  
; OTHER INFORMATION: g29491  
US-09-172-977-4

Query Match 11.1%; Score 228.5; DB 2; Length 1839;  
Best Local Similarity 29.5%; Pred. No. 1.8e-14;  
Matches 74; Conservative 36; Mismatches 102; Indels 39; Gaps 5;  
QY 143 LHRAMWGKVPKRDILVMLRDTDV--NKKDKQKRTALHLASANGNSEVVKLLLDRCQLN 200  
DB 534 LHSAREGV---DVASVLEGAARHSLATKKGFTPLHVAAKYGLSDVAKLLLQRRRAAD 590  
QY 201 VLDNKKRTALIKAVQCEDECALMLLEHGTDPNIPDEYGNNTLHYAIYNEDKLMKALLL 260  
DB 591 SAGKNGLTPLHVAHYDNQKVALLEKASPHATAGNYTPHLIAAKKNQMQIATSTLLN 650  
QY 261 YGADIESKNKHGTLPTLLGVHEQKQOVVKFLIKKANLNALDRYGRITALILA----- 312  
DB 651 YGAETNIVTKOGVTPHLIASQEGHGTDMVTLLLDKGANIHMTSKGSLTSLHLAAQEDKVV 710  
QY 313 -----VCC--GSASIVSLLEQNIIDVSSQDLSGGOT-AREYAV 346  
DB 711 ADILTKHGADQDAHTKLGTYPLIVACHYGNVKVNFLLKOGANVNAKTKNGYTPHLQAAQ 770  
QY 347 SSHHVICOLL 357  
DB 771 QGHTHIINVLL 781

## RESULT 14

US-09-196-387-10  
; Sequence 10, Application US/09196387  
; Patent No. 6277613  
; GENERAL INFORMATION:  
; APPLICANT: de Lange, Titia  
; APPLICANT: Smith, Susan  
; TITLE OF INVENTION: A PROTEIN THAT BINDS TO TRF1 AND METHODS  
; TITLE OF INVENTION: OF USE THEREOF  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Klauber & Jackson  
; CITY: Hackensack  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 07601  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/196,387  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/095,225  
; FILING DATE: June 10, 1998  
; ATTORNEY/AGENT INFORMATION:

```
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-230 CIPI
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800
; TELEFAX: 201-343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 949 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-196-387-10

Query Match          10.9%; Score 226; DB 4; Length 949;
Best Local Similarity 26.0%; Pred. No. 1.3e-14;
Matches 82; Conservative 37; Mismatches 114; Indels 82; Gaps 6;

QY 137 GEDLDKHLHRAAWGKVPKRDILVIMLRDITVNNKDKQKRTALHLASANGSEVVKLLDRL 196
Db 367 GRKSTPLHLAAGYNRV-RIVQLLQHGADVHAKDKGLVPLHNACSYGHVEVTELLKHG 425

QY 197 COLNVLDNKKRTALIKAVQCOEDECALMLLEHGTDPNIPDEYG----- 239
Db 426 ACVNAMDLMQFTPLHEAASKNRVEVCSILLSHGADPTLVNCHGKSAVDMAPTPELRERLT 485

QY 240 -----NTTLHYAI---YNEDKLMAKALL 259
Db 486 YEFKSHLSLQAAAREADLAKVKKTLALEINFKQPSHETALHCASVSLHPKRRQVTELL 545

QY 260 LYGADIESKNKGLTPLLLVGHEQKQVVKFLKKKANLALDRYGRRTALILAVCCGSAS 319
Db 546 RKGANVNEKNKDFMTPHLVAERAHNDVMEVLHKGAKMNAALDTLQGTALHRAALAGHLQ 605

QY 320 IVSLLLEQNIDVSSQDLSGQTAREYAVSSHHHVICQLLS-----DYKEKQMLK-- 367
Db 606 TCRLLSYGSDFSIISLQGTAAQMG-----NEAVQILSESTPIRTSDVDYRLLEASKAG 661

QY 368 -----ISSENSN 374
Db 662 DLETVKQLCSSQNVN 676

RESULT 15
US-09-196-387-2
; Sequence 2, Application US/09196387
; Patent No. 6277613
; GENERAL INFORMATION:
; APPLICANT: de Lange, Titia
; APPLICANT: Smith, Susan
; TITLE OF INVENTION: A PROTEIN THAT BINDS TO TRF1 AND METHODS
; TITLE OF INVENTION: OF USE THEREOF
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Klauber & Jackson
; STREET: 411 Hackensack Avenue, 4th Floor
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/196,387
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/095,225
```

```
; FILING DATE: June 10, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-230 CIPI
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800
; TELEFAX: 201-343-1684
; TELEX: 133521
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1327 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; US-09-196-387-2

Query Match          10.9%; Score 226; DB 4; Length 1327;
Best Local Similarity 26.0%; Pred. No. 2.1e-14;
Matches 82; Conservative 37; Mismatches 114; Indels 82; Gaps 6;

QY 137 GEDLDKHLHRAAWGKVPKRDILVIMLRDITVNNKDKQKRTALHLASANGSEVVKLLDRL 196
Db 367 GRKSTPLHLAAGYNRV-RIVQLLQHGADVHAKDKGLVPLHNACSYGHVEVTELLKHG 425

QY 197 COLNVLDNKKRTALIKAVQCOEDECALMLLEHGTDPNIPDEYG----- 239
Db 426 ACVNAMDLMQFTPLHEAASKNRVEVCSILLSHGADPTLVNCHGKSAVDMAPTPELRERLT 485

QY 240 -----NTTLHYAI---YNEDKLMAKALL 259
Db 486 YEFKSHLSLQAAAREADLAKVKKTLALEINFKQPSHETALHCASVSLHPKRRQVTELL 545

QY 260 LYGADIESKNKGLTPLLLVGHEQKQVVKFLKKKANLALDRYGRRTALILAVCCGSAS 319
Db 546 RKGANVNEKNKDFMTPHLVAERAHNDVMEVLHKGAKMNAALDTLQGTALHRAALAGHLQ 605

QY 320 IVSLLLEQNIDVSSQDLSGQTAREYAVSSHHHVICQLLS-----DYKEKQMLK-- 367
Db 606 TCRLLSYGSDFSIISLQGTAAQMG-----NEAVQILSESTPIRTSDVDYRLLEASKAG 661

QY 368 -----ISSENSN 374
Db 662 DLETVKQLCSSQNVN 676

Search completed: August 28, 2002, 11:29:32
Job time: 250 sec
```

-----



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 28, 2002, 11:20:12 ; Search time 32.5 Seconds  
(without alignments)  
1312.380 Million cell updates/sec

Title: US-09-810-936-304  
 Perfect score: 2064  
 Sequence: 1 MVVEVDSMPAASSYKKPFGI.....MTKISSNSNPENVSRTRNK 384

Scoring table: BLOSUM62  
Gapop 10.0 : Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 s

Database :

A\_Geneseq\_032802.\*

1:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1980.DAT.*
2:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1981.DAT.*
3:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1982.DAT.*
4:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1983.DAT.*
5:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1984.DAT.*
6:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1985.DAT.*
7:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1986.DAT.*
8:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1987.DAT.*
9:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1988.DAT.*
10:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1989.DAT.*
11:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1990.DAT.*
12:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1991.DAT.*
13:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1992.DAT.*
14:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1993.DAT.*
15:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1994.DAT.*
16:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1995.DAT.*
17:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1996.DAT.*
18:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1997.DAT.*
19:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1998.DAT.*
20:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA1999.DAT.*
21:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA2000.DAT.*
22:	/SDSI1/gcgdata/hold-geneseq/geneseqp-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query %		Length	DB	ID	Description
		Match					
1	2064	100.0	384	21	AAB28628		Human B1lAgl anti
2	2064	100.0	384	22	AAG55978		B305D isoform C sp
3	2064	100.0	1719	21	AAV82017		Human immunogenic
4	2064	100.0	1719	22	AAU69777		Human prostate cDN
5	2064	100.0	1719	22	ARM01132		Human prostate-spe
6	2064	100.0	1719	22	AAG99017		Human prostate-spe
7	2064	100.0	1719	22	AAB74815		Prostate tumour an
8	2024	98.1	656	21	AAG28629		Human B1lAgl anti
9	2024	98.1	656	21	AAV82018		Human immunogenic
10	2024	98.1	656	22	AAG55977		B305D isoform C sp
11	2024	98.1	656	22	AAU69778		Human prostate cDN

12	2024	98.1	656	22	AAM01133	Human prostate-spe
13	2024	98.1	656	22	AAG99018	Human prostate-spe
14	2024	98.1	656	22	AAB74816	Prostate tumour an
15	2024	98.1	671	21	AAB28630	Human BllAg1 anti
16	2024	98.1	671	21	AAY82019	Human immunogeni
17	2024	98.1	671	22	AAG52019	B305D isoform C sp
18	2024	98.1	671	22	AAG52978	Human prostate cDN
19	2024	98.1	671	22	AAU69779	Human prostate-spe
20	2024	98.1	671	22	AAM01134	Human prostate-spe
21	2024	98.1	671	22	AAG99019	Human prostate-spe
22	2024	98.1	671	22	AAB74817	Prostate tumour an
23	1314	63.7	292	21	AAB28636	Human breast tumo
24	1314	63.7	292	22	AAG56975	B305D isoform A se
25	1314	63.7	292	22	AAG59821	Human prostate cDN
26	1314	63.7	292	22	AAM01176	Human prostate-spe
27	1136	55.0	329	22	AAG99061	Human prostate-spe
28	1136	55.0	329	21	AAB28626	Human BllAg1 anti
29	1136	55.0	329	21	AAY82015	Human immunogeni
30	1136	55.0	329	22	AAG53974	B305D isoform A fl
31	1136	55.0	329	22	AAG59775	Human prostate cDN
32	1136	55.0	329	22	AAM01130	Human prostate-spe
33	1136	55.0	329	22	AAG99015	Human prostate-spe
34	628.5	30.5	546	22	AAB74813	Prostate tumour an
35	623	30.2	148	21	AAB28627	Human BllAg1 anti
36	623	30.2	148	21	AAY82016	Human immunogeni
37	623	30.2	148	22	AAU69776	Human prostate cDN
38	623	30.2	148	22	AAM01131	Human prostate-spe
39	623	30.2	148	22	AAG99016	Human prostate-spe
40	623	30.2	148	22	AAB74814	Prostate tumour an
41	544.5	26.4	239	22	AAM93703	Human polypeptide,
42	522	25.3	1341	22	AAB84702	Amino acid sequenc
43	520.5	25.2	232	21	AAB41851	Human OPFX ORF1615
44	497.5	24.0	225	22	ABG94083	Novel human diagno
45	493	23.9	218	20	AAY36106	Extended human sec

ALIGNMENTS

RESULT 1

AA28628

ID AAB28628 standard; Protein; 384 AA.

AC AAB28628;

DT 13-FEB-2001 (first entry)

DE Human BllAg1 antigen splice isoform Bllc-15.

DE Human; breast tumour-specific antigen; cytostatic; vaccine;

KW breast cancer; BllAg1; BllAg1; BllAg1.

KW

OS Homo sapiens.

PN WO200061753-A2.

PN

PD 19-OCT-2000.

PD

PF 07-APR-2000; 2000WO-US09312.

PF

XX 09-APR-1999; 99US-0289198.

XX 28-OCT-1999; 99US-0429755.

XX 23-MAR-2000; 2000US-0534825.

XX

PA (CORI-) CORIXA CORP.

PA

PI Frudakis TN, Smith JM, Reed SG, Misher LE, Retter MW, Dillon DC;

PI

DR WPI; 2000-628403/60.

DR N-PSDB; AAC81011.

DR

XX

XX An isolated polypeptide comprising an immunogenic portion of a breast

PT tumour protein used for inhibiting the development of cancer especially

PT breast cancer, and monitoring cancer progression in a patient -  
PS Claim 3; Page 179; 187pp; English.  
XX  
XX The present sequence is given in a specification relating to compositions  
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide  
CC sequences that are preferentially expressed in breast tumour tissue, and  
CC the polypeptides encoded by such nucleotide sequences, are used in  
CC compositions and vaccines to inhibit the development of cancer,  
CC especially breast cancer. The progression of a cancer may be monitored by  
CC carrying out detection of tumour-specific antigens at subsequent time  
CC points and comparing the results from the different time points.  
CC CD4+ and/or CD8+ T-Cells isolated from the cancer patient may be treated  
CC with tumour-specific polypeptides, polynucleotides encoding the  
CC polypeptides or antigen presenting cells expressing the polypeptides. The  
CC cells are then administered to the patient to inhibit development of  
CC cancer.  
XX  
XX Sequence 384 AA;  
SQ  
Query Match 100.0%; Score 2064; DB 21; Length 384;  
Best Local Similarity 100.0%; Pred. No. 2.1e-193;  
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVVEVDSMPAASSVKKPFGLRSKMGKWCRCPCPCRESGKSNVGTSGDHDSAMKTLRSK 60  
Db 1 mvvevdsmpaassvkkpfglrskmgkwcrcpcpcresgksnvgtsgdhdsamktlrsk 60  
QY 61 MGKWCRCPCPCRESGKSNVGTSGDHDSAMKTLRNKMGKWCRCPCPCRESGSKSVGAW 120  
Db 61 mgkwcrcpcpcresgksnvgtsgdhdsamktlrnmgkwcrcpcpcresgsksvgaw 120  
QY 121 GDYDTSAPMEPRYHVRGEDIKLRHAAWKGKVPKDLIVMLRDTDVNKKDKOKRTALHLA 180  
Db 121 gdydtsafmepryhvrgeidklhraawkgkvpkdlivmlrtdvnnkdkkrtalhl 180  
QY 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCOEDECALMLEHGTDPNIPDEYGN 240  
Db 181 sangnsevvkllldrrcqlnvldnkkrtalikaavqcedecalmllehgtdpnipdeygn 240  
QY 241 TTLHYAIYNEDKLMKALLLYGADIESKNKHGLTPLLIGVHEQKQOVVKFLIKKANLNA 300  
Db 241 ttlhyaiynedklmakalllygadiesknkhgltplllgvheqkqvkvflikkanlna 300  
QY 301 LDYGRRTALILAVCCGSASIVSLLEQNDIVSSQDLSGOTAREYAVSSHVHVICOLLSDY 360  
Db 301 ldrygrtallilavccgsasivslleqndivssqdisgqtareyavsshhvivicqlsdy 360  
QY 361 KEQMKIKISSENSNPENVSRTNRK 384  
Db 361 kekqmkikisensnpenvsrtnrk 384  
RESULT 2  
AAG65976  
ID AAG65976 standard; Protein; 384 AA.  
XX  
XX AAG65976;  
AC  
XX  
XX 11-FEB-2002 (first entry)  
XX  
XX B305D isoform C splice variant 1.  
XX  
XX Genetic subtraction; DNA microarray analysis; polymerase chain reaction;  
KW cancer; B305D.  
XX  
XX Homo sapiens.  
XX  
XX WO200175171-A2.  
XX  
XX 11-OCT-2001.  
XX

PF 02-APR-2001; 2001WO-US10631.  
XX  
PR 03-APR-2000; 2000US-194241P.  
PR 20-JUL-2000; 2000US-219862P.  
PR 27-JUL-2000; 2000US-221300P.  
PR 18-DEC-2000; 2000US-256592P.  
XX  
XX (CORI-) CORIXA CORP.  
XX  
XX Houghton RL, Dillon DC, Molesh DA, Xu J, Zehentner B, Persing DH;  
PI WPI; 2001-626449/72.  
XX N-PSDB; AA167211.  
DR  
XX Identifying tissue (tumour)-specific polynucleotides overexpressed in  
PT tissue of interest as compared to control tissue, for detecting cancer  
PT cells in patient, comprises DNA microarray analysis or quantitative  
PT polymerase chain reaction -  
XX  
XX Examples; Page 95-96; 127pp; English.  
PS  
XX The invention relates to identifying tissue-specific polynucleotides (P)  
CC that involves performing a genetic subtraction to identify pool of (P)  
CC from tissue of interest (TI), performing DNA microarray analysis to  
CC identify first subset of polynucleotides (S1) at least 2-fold over  
CC expressed in TI, and performing quantitative polymerase chain reaction  
CC (PCR) analysis on S1 to identify second subset of (P). The method is  
CC useful for determining the presence or absence of a cancer cell in a  
CC patient, monitoring the progression of cancer in a patient using a  
CC biological sample such as blood, serum, lymph nodes, bone marrow, sputum,  
CC urine or a tumour biopsy sample. The methods are useful for determining  
CC the presence or absence of or monitoring progression of prostate, breast,  
CC colon, ovarian, lung, head and neck, lymphoma, leukemia, melanoma, liver,  
CC gastric, kidney, bladder, pancreatic or endometrial cancer. The present  
CC sequence represents a B305D isoform C splice variant.  
XX  
XX Sequence 384 AA;  
SQ  
Query Match 100.0%; Score 2064; DB 22; Length 384;  
Best Local Similarity 100.0%; Pred. No. 2.1e-193;  
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVVEVDSMPAASSVKKPFGLRSKMGKWCRCPCPCRESGKSNVGTSGDHDSAMKTLRSK 60  
Db 1 mvvevdsmpaassvkkpfglrskmgkwcrcpcpcresgksnvgtsgdhdsamktlrsk 60  
QY 61 MGKWCRCPCPCRESGKSNVGTSGDHDSAMKTLRNKMGKWCRCPCPCRESGSKSVGAW 120  
Db 61 mgkwcrcpcpcresgksnvgtsgdhdsamktlrnmgkwcrcpcpcresgsksvgaw 120  
QY 121 GDYDTSAPMEPRYHVRGEDIKLRHAAWKGKVPKDLIVMLRDTDVNKKDKOKRTALHLA 180  
Db 121 gdydtsafmepryhvrgeidklhraawkgkvpkdlivmlrtdvnnkdkkrtalhl 180  
QY 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCOEDECALMLEHGTDPNIPDEYGN 240  
Db 181 sangnsevvkllldrrcqlnvldnkkrtalikaavqcedecalmllehgtdpnipdeygn 240  
QY 241 TTLHYAIYNEDKLMKALLLYGADIESKNKHGLTPLLIGVHEQKQOVVKFLIKKANLNA 300  
Db 241 ttlhyaiynedklmakalllygadiesknkhgltplllgvheqkqvkvflikkanlna 300  
QY 301 LDYGRRTALILAVCCGSASIVSLLEQNDIVSSQDLSGOTAREYAVSSHVHVICOLLSDY 360  
Db 301 ldrygrtallilavccgsasivslleqndivssqdisgqtareyavsshhvivicqlsdy 360  
QY 361 KEQMKIKISSENSNPENVSRTNRK 384  
Db 361 kekqmkikisensnpenvsrtnrk 384  
RESULT 3

AAV82017  
ID AAV82017 standard; Protein; 1719 AA.  
AC AAV82017;  
DT 13-JUN-2000 (first entry)  
XX Human immunogenic prostate tumour protein sequence SEQ ID NO:378.  
DE Human; prostate cancer; diagnosis; tumour; gene therapy; detection;  
KW immunogenic; cytostatic; vaccine.  
OS Homo sapiens.  
XX WO200004149-A2.  
PN 27-JAN-2000.  
PD 14-JUL-1999; 99WO-0515838.  
PF 14-JUL-1998; 98US-0115453.  
PR 14-JUL-1998; 98US-0116134.  
PR 23-SEP-1998; 98US-0159612.  
PR 23-SEP-1998; 98US-0159622.  
PR 15-JAN-1999; 99US-0232149.  
PR 15-JAN-1999; 99US-0232880.  
PR 09-APR-1999; 99US-0288946.  
XX (CORI-) CORIXA CORP.  
PA Dillon DC, Harlocker SL, Yuqiu J, Xu J, Mitcham JL;  
PI WPI; 2000-171268/15.  
DR New polypeptide useful for treating and diagnosing prostate cancer  
PT comprises an immunogenic portion of prostate tumor protein -  
XX Disclosure; Page 225-229; 263pp; English.  
XX The present invention describes isolated polypeptides, comprising an  
CC immunogenic portion of a prostate tumour protein (PTP). The polypeptides  
CC and polynucleotides encoding them have cytostatic activity and can be  
CC used in vaccines and in gene therapy. The polypeptides and  
CC polynucleotides encoding them, antigen presenting cells which express  
CC the polypeptides, antibodies against the polypeptides and vaccines  
CC comprising them can be used for inhibiting the development of prostate  
CC cancer in a patient. The polypeptides can be used to generate antibodies  
CC or anti-idiotypic antibodies for passive immuno therapy. A portion of  
CC the polynucleotides encoding the polypeptides can be used as a probe or  
CC to modulate the expression of the polypeptides. AA06241 to AA06691 and  
CC AAV82000 to AAV82020 represent sequences used in the exemplification of  
CC the present invention.  
XX Sequence 1719 AA;  
SQ

Query Match  
Best Local Similarity 100.0%; Score 2064; DB 21; Length 1719;  
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVEVDSPAASSVKKPFGLRKMGMKWCRCFPCCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvevdspaaassvkkpfglrskmgkwcrcfpccresgknsnvtsgdhdssamtklrsk 60  
QY 61 MGKWCRCFPCCRESGKSNVGSAGDHDSDAMKTLRNMKGWCRCFPCCRGSKSKVGAW 120  
Db 61 mgkwcrcfpccrgsgksnvgsagdhdsamtklrnmkgkwcrcfpccrgsgkskvaw 120  
QY 121 GDYDSDAPMEPRYHVRCEDLDLHRAAWGKVPKDLIVMLRDTYNNKDKQKFRALHLA 180  
Db 121 gdydssdamepryinvrgedldlhraawgkvpkrkdlivmlrtdvnnkdkqkfralhla 180  
QY 181 SANGNSEVVKLLLDRCQLNVLNDNKRRTALIKAVQCQDECALMLLEHGTDPNIPDEYGN 240

Db 181 sangnsevvkllldrrcqlnvldnkkrtallikavqcqdecalmllehgtdpnpideygn 240  
QY 241 TTLHYAIYNEDKILMAKALLYGADIESKNKHGLTPLLIGVHEKQOVVKFLIKKANLNA 300  
Db 241 ttlhyaiynedkilmakalliygadiesknkhgltplllgvheqkqvkvflikkkanlna 300  
QY 301 LDRYGRFTALIAVCCSASIVSLLEQNIQVSSQDLISGQTAREYAVSSHVHCQLLSDY 360  
Db 301 ldrygrftallavccsasivslilleqnidvssqdlisggtareyavsshvhvicqlsdy 360  
QY 361 KEKOMLKISSENPNVSRTRNK 384  
Db 361 kekqmkkissennpvnsvrtrnk 384  
RESULT 4  
AAU69777  
ID AAU69777 standard; Protein; 1719 AA.  
XX AAU69777;  
AC AAU69777;  
DT 30-JAN-2002 (first entry)  
DE Human prostate cDNA encoded protein #15.  
DE Human; prostate cancer; cytostatic; immunostimulant; tumour; immunogen.  
KW Homo sapiens.  
XX WO200173032-A2.  
PD 04-OCT-2001.  
PF 27-MAR-2001; 2001WO-US09919.  
PR 27-MAR-2000; 2000US-0536857.  
PR 09-MAY-2000; 2000US-0568100.  
PR 12-MAY-2000; 2000US-0570737.  
PR 13-JUN-2000; 2000US-0593793.  
PR 27-JUN-2000; 2000US-0605783.  
PR 10-AUG-2000; 2000US-0636215.  
PR 29-AUG-2000; 2000US-0651236.  
PR 06-SEP-2000; 2000US-0657279.  
PR 02-OCT-2000; 2000US-0679426.  
PR 10-OCT-2000; 2000US-0685166.  
XX (CORI-) CORIXA CORP.  
PA Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;  
PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedwick TS, Carter D;  
PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;  
XX WPI; 2001-639232/73.  
DR N-PSDB; AAS63807.  
XX New human prostate-specific polypeptides and polynucleotides useful for  
PT the diagnosis and treatment of cancer, especially prostate cancer -  
XX Claim 2; Page 352-356; 579pp; English.  
XX The invention relates to isolated prostate-specific  
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,  
CC antibodies raised against the polypeptides (or antigenic epitopes  
CC derived from them) and antigen-presenting cells expressing the  
CC polypeptides. The antibodies are useful for detecting the presence of  
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and  
CC the antigen-presenting cells are useful for stimulating and/or expanding  
CC T cells specific for a tumour protein, and for inhibiting the development  
CC of cancer especially prostate cancer. Compositions comprising the  
CC polynucleotide and/or polypeptide are useful for stimulating an immune  
CC response, and for treating cancer. The oligonucleotide is useful for  
CC detecting cancer. The present sequence is a prostate specific

CC	polypeptide of the invention.	PS	Claim 2; Page 350-354; 543pp; English.
XX		XX	The present invention describes polynucleotide sequences (I) which encode
SQ	Sequence 1719 AA;	CC	prostate-specific proteins (II). (I) and (II) have cytostatic activity,
		CC	and can be used in vaccine production and gene therapy. (I), (II),
		CC	antibodies to (II), fusion proteins comprising (II), and isolated
		CC	T cells prepared using (I) or (II) are used to treat cancer in a patient.
		CC	(I) and the antibodies are also used in the detection of cancer in a
		CC	patient. The cancer that is diagnosed or treated is particularly
		CC	prostate cancer. (I) and (II) can be used in vaccines. The antibodies or
		CC	(I) can be used for monitoring the progression of cancer in a patient.
		CC	(I) and (II) can also be used to improve diagnostic and therapeutic
		CC	methods for prostate cancer. They can indicate the level of metastasis
		CC	as well as the prostate volume. AA93357 to AA93944 and AA01115 to
		CC	AA01318 represent polynucleotide and amino acid sequences used in the
		CC	exemplification of the present invention.
		XX	
		SQ	Sequence 1719 AA;
		Query Match	100.0%; Score 2064; DB 22; Length 1719;
		Best Local Similarity	100.0%; Pred. No. 1.8e-192;
		Matches 384; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MVEVDSMPAASVKKPGLSKMGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRSK 60	QY	1 MVEVDSMPAASVKKPGLSKMGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRSK 60
DB	1 mvevdsmpaasvkkpfglrskmgkwcrcfpcrcresgksnvgtsghdhsamktlrsk 60	DB	1 mvevdsmpaasvkkpfglrskmgkwcrcfpcrcresgksnvgtsghdhsamktlrsk 60
QY	61 MGKWCRCPCPCRCGSGKSNVGSAGDHDSDAMKTLRNKMGKWCCHCPCPCRCGSGSKVGAW 120	QY	61 MGKWCRCPCPCRCGSGKSNVGSAGDHDSDAMKTLRNKMGKWCCHCPCPCRCGSGSKVGAW 120
DB	61 mgkwcrcfpcrcrgsgksnvgasghdhsamktlrnkmgkwcchcpcrcrgsgkskvga 120	DB	61 mgkwcrcfpcrcrgsgksnvgasghdhsamktlrnkmgkwcchcpcrcrgsgkskvga 120
QY	121 GDYDSDAFMEPRYHVRGDLKHLRAAWGKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180	QY	121 GDYDSDAFMEPRYHVRGDLKHLRAAWGKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180
DB	121 gdydsafmepryhvrgehdlkhlraawgkvpkdlivmlrtdtdvnnkdkqkrtalhla 180	DB	121 gdydsafmepryhvrgehdlkhlraawgkvpkdlivmlrtdtdvnnkdkqkrtalhla 180
QY	181 SANGNSEVVKLLDRRCOLNVLDNKKRTALIKAVOCQEDCALMLEHGTDPNIPDEYGN 240	QY	181 SANGNSEVVKLLDRRCOLNVLDNKKRTALIKAVOCQEDCALMLEHGTDPNIPDEYGN 240
DB	181 sangnsevkllldrrcqlnvldnkkrtalikavqcqedeccalmlehgtdpnipdeygn 240	DB	181 sangnsevkllldrrcqlnvldnkkrtalikavqcqedeccalmlehgtdpnipdeygn 240
QY	241 TTLHYAIYNEDKIMAKALLYGADIESKNKHGLTPLLGVHEQKQOVVKFLIKKANLNA 300	QY	241 TTLHYAIYNEDKIMAKALLYGADIESKNKHGLTPLLGVHEQKQOVVKFLIKKANLNA 300
DB	241 ttlhyaiynedkimakalliygadiesknkhgltplllgvheqgqvkvfllkkanlna 300	DB	241 ttlhyaiynedkimakalliygadiesknkhgltplllgvheqgqvkvfllkkanlna 300
QY	301 LDYGRPTALILAVCCGSASIVSLLEQNIDVSSQDLSGQTAREYAVSSHVVICQLSDY 360	QY	301 LDYGRPTALILAVCCGSASIVSLLEQNIDVSSQDLSGQTAREYAVSSHVVICQLSDY 360
DB	301 ldrygrtalilavccgsasivslilleqnidvssqdsqsgqtareyavsshvhvicolisdy 360	DB	301 ldrygrtalilavccgsasivslilleqnidvssqdsqsgqtareyavsshvhvicolisdy 360
QY	361 KEQOMLKISSENSNPENVSRTNRK 384	QY	361 KEQOMLKISSENSNPENVSRTNRK 384
DB	361 kekqmlkissensnpensvtrnrk 384	DB	361 kekqmlkissensnpensvtrnrk 384
		RESULT 6	
		AAAG99017	
		ID	AAAG99017 standard; Protein; 1719 AA.
		XX	
		AC	AAAG99017;
		XX	
		DT	25-SEP-2001 (first entry)
		XX	
		DE	Human prostate-specific amino acid sequence B305D splice variant #3.
		XX	
		KW	Human; prostate cancer; therapy; diagnosis; cat eye syndrome;
		KW	chromosome 22q11.2; prostate-specific protein; chromosome 1;
		KW	prostate specific antigen; PSA.
		XX	
		OS	Homo sapiens.
		XX	
		FN	WO200134802-A2.
		XX	
		PD	17-MAY-2001.
		XX	

```

PF XX 09-NOV-2000; 2000WO-US30504.
PR XX 12-NOV-1999; 99US-0439313.
PR XX 18-NOV-1999; 99US-0443686.
XX XX (CORI-) CORIXA CORP.
XX XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;
PI PI Kalos MD, Retter MW, Stolk JA, Day CH, Skeiky YAW, Wang A;
XX XX WPI; 2001-308785/32.
XX XX
XX XX Isolated polypeptide comprising at least an immunogenic portion of a
PT PT prostate-specific protein, useful in the diagnosis and therapy of a
PT PT prostate cancer -
XX XX
XX XX Disclosure; Page 250-253; 325pp; English.
XX XX
XX XX The present invention describes an isolated polypeptide (P1) comprising
CC CC at least an immunogenic portion of a prostate-specific protein, or its
CC CC variant. Also described are polynucleotides (N1) encoding (P1). (P1) and
CC CC (N1) have cytostatic activity and can be used in vaccine production.
CC CC The polypeptides, nucleic acids and antibodies from the present
CC CC invention are useful in the diagnosis and therapy of prostate cancer.
CC CC Prostate specific genes P704P, P712P, P774P, P775P and B305D are located
CC CC in a genomic region on chromosome 22q11.2 known as the Cat Eye Syndrome
CC CC region. Prostate specific antigen (PSA) P501S was located on
CC CC chromosome 1. AAB84671 to AAB85143 and AAG99000 to AAG99077 represent
CC CC polynucleotide and polypeptide sequences used in the exemplification
CC CC of the present invention.
XX XX
XX XX Sequence 1719 AA;

Query Match 100.0%; Score 2064; DB 22; Length 1719;
Best Local Similarity 100.0%; Pred. No. 1.8e-192;
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVVEVDSMPAASSVKKPFGLRSKMGKWCRCFPCCRESGSKSNVGTSGDHDSDSAMKTLRSK 60
Db 1 mvvevdsmpaassvkkpfglrskmgkwcrcfpcrcresgsksnvgtsgdhdssamktlrsk 60
QY 61 MGKWCRCFCPCRCGSGSKSNVGASGDHDDSDSAMKTLRNKMGKWCRCFCPCRCGSGSKSVGAW 120
Db 61 mgkwcrcfcpcrcgsgsksnvgasgdhdssamktlrnkmgkcwcrcfcpcrcgsgsksvgaw 120
QY 121 GDYDSDAFMEPRYHYVRGEDLDKLRHAAWGWKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180
Db 121 gdydsdafmepryhvrgehdlkhrhAAWGWKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180
QY 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCDECALMLEHGTDPNIPDEYGN 240
Db 181 sangnsevvkllldrrcqnlvldnkkrtalikavqcgedecalmllehgtdpnipdeygn 240
QY 241 TTLHYAIYNEDKLMAKALLYGADIESKNKHGLTPLLGVHEQKQOVVFKLKKKANLNA 300
Db 241 ttlhyaiynedklmakalllygadiesknkhgltplllgvheqkqvkvfllkkanlna 300
QY 301 LDYRGRTALILAVCCGSASIVSLLEQNIDVSSODLSGOTAREYAVSSHHHVICQLLSDY 360
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgotareyavsshhhviciqllsdy 360
QY 361 KEQMKLTSSNSPNVSTRNK 384
Db 361 kekqmkltssnsnpnvstrnk 384

RESULT 7
AAB74815
ID AAB74815 standard; Protein; 1719 AA.
XX XX
AC AAB74815;
XX XX

```

```

DT 14-JUN-2001 (first entry)
XX XX Prostate tumour antigen splice variant of B305D amino acid sequence #3.
DE XX Human; prostate tumour antigen; prostate tumour; therapy; diagnosis;
KW KW prostate cancer; immunogenic; cytostatic; vaccine.
XX XX Homo sapiens.
OS OS WO200125272-A2.
PN PN 12-APR-2001.
PD PD 04-OCT-2000; 2000WO-US27464.
XX XX 04-OCT-1999; 99US-0157455.
PR PR (CORI-) CORIXA CORP.
XX XX Xu J, Skeiky YAW, Reed SG, Cheever MA;
PI PI WPI; 2001-245062/25.
XX XX N-PSDB; AAB02779.
DR DR
XX XX Prostate specific protein and its encoding polynucleotide, useful for
PT PT the treatment and diagnosis of prostate cancer -
PT PT
XX XX Disclosure; Page 235-238; 276pp; English.
XX XX
XX XX The present invention describes an isolated polypeptide (I) comprising
CC CC at least an immunogenic portion of a prostate tumour antigen protein or
CC CC its variant. (I) have cytostatic activity and can be used in vaccine
CC CC production. (I), prostate tumour antigen polynucleotides, an antigen
CC CC presenting cell (APC e.g. a dendritic cell) that expresses (I), and a
CC CC pharmaceutical composition containing (I) are useful for inhibiting the
CC CC development of cancer in a patient. Antibodies specific for prostate
CC CC specific proteins and oligonucleotides that hybridise to a
CC CC polynucleotide that encodes a prostate specific protein are useful
CC CC for detecting the presence or absence of a cancer or monitoring the
CC CC progression the progression of a cancer, especially prostate cancer.
CC CC AAB02422 to AAB2872, AAB74798 to AAB74821 and AAB74830 are sequences
CC CC used in the exemplification of the present invention.
XX XX
XX XX Sequence 1719 AA;

Query Match 100.0%; Score 2064; DB 22; Length 1719;
Best Local Similarity 100.0%; Pred. No. 1.8e-192;
Matches 384; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MVVEVDSMPAASSVKKPFGLRSKMGKWCRCFPCCRESGSKSNVGTSGDHDSDSAMKTLRSK 60
Db 1 mvvevdsmpaassvkkpfglrskmgkwcrcfpcrcresgsksnvgtsgdhdssamktlrsk 60
QY 61 MGKWCRCFCPCRCGSGSKSNVGASGDHDDSDSAMKTLRNKMGKWCRCFCPCRCGSGSKSVGAW 120
Db 61 mgkwcrcfcpcrcgsgsksnvgasgdhdssamktlrnkmgkcwcrcfcpcrcgsgsksvgaw 120
QY 121 GDYDSDAFMEPRYHYVRGEDLDKLRHAAWGWKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180
Db 121 gdydsdafmepryhvrgehdlkhrhAAWGWKVPKDLIVMLRDTDVNKKDKQKRTALHLA 180
QY 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCDECALMLEHGTDPNIPDEYGN 240
Db 181 sangnsevvkllldrrcqnlvldnkkrtalikavqcgedecalmllehgtdpnipdeygn 240
QY 241 TTLHYAIYNEDKLMAKALLYGADIESKNKHGLTPLLGVHEQKQOVVFKLKKKANLNA 300
Db 241 ttlhyaiynedklmakalllygadiesknkhgltplllgvheqkqvkvfllkkanlna 300
QY 301 LDYRGRTALILAVCCGSASIVSLLEQNIDVSSODLSGOTAREYAVSSHHHVICQLLSDY 360
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgotareyavsshhhviciqllsdy 360

```

QY 361 KEKOMLKISSENSNPENSVTRNK 384  
DB 361 kekqmlkissensnpensvtrnk 384

RESULT 8  
ID AAB28629 standard; Protein; 656 AA.  
XX AAB28629;  
XX AAB28629;  
DT 13-FEB-2001 (first entry)  
XX Human B11Ag1 antigen splice isoform B11C-8.  
XX Human; breast tumour-specific antigen; cytostatic; vaccine;  
XX breast cancer; B18Ag1; B15Ag1.  
XX Homo sapiens.  
XX WO2000061753-A2.  
XX 19-OCT-2000.  
XX 07-APR-2000; 2000WO-US09312.  
XX 09-APR-1999; 99US-0289198.  
XX 28-OCT-1999; 99US-0429755.  
XX 23-MAR-2000; 2000US-0534825.  
XX (CORI-) CORIXA CORP.  
XX Frudakis TN, Smith JM, Reed SG, Misher LE, Retter MW, Dillon DC;  
XX WPI: 2000-628403/60.  
XX N-PSDB; AAC81012.  
XX An isolated polypeptide comprising an immunogenic portion of a breast  
XX tumor protein used for inhibiting the development of cancer, especially  
XX breast cancer, and monitoring cancer progression in a patient -  
XX Claim 3; Page 180-181; 187pp; English.

XX The present sequence is given in a specification relating to compositions  
XX and methods for the treatment and diagnosis of breast cancer. Nucleotide  
XX sequences that are preferentially expressed in breast tumour tissue, and  
XX the polypeptides encoded by such nucleotide sequences, are used in  
XX compositions and vaccines to inhibit the development of cancer,  
XX especially breast cancer. The progression of a cancer may be monitored by  
XX carrying out detection of tumour-specific antigens at subsequent time  
XX points and comparing the results from the different time points.  
XX CD4+ and/or CD8+ T-Cells isolated from the cancer patient may be treated  
XX with tumour-specific polypeptides, polynucleotides encoding the  
XX polypeptides or antigen presenting cells expressing the polypeptides. The  
XX cells are then administered to the patient to inhibit development of  
XX cancer.  
XX Sequence 656 AA;

Query Match 98.1%; Score 2024; DB 21; Length 656;  
Best Local Similarity 100.0%; Pred. No. 3.7e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVEVDSPAASSVKKPFGLRSMKWKCCRCPCCRSGKSNVGTSGDHDSDAMKTLRSK 60  
DB 1 mvvevdspaaassvkkpfglrsmkwcrcpcrcsgksnvgtsghdhdhsamtklrsk 60  
QY 61 MGKWCRCPCCRSGKSNVGSAGDHDSDAMKTLRNKMGKWCCHCPCCRSGSKSKVGAW 120  
DB 61 mgkwcrcpcrcsgksnvgasgdhdhsamtklrnmkgkwccchcpcrcrgsgkskvga 120

QY 121 GDYDSSAFMEPRYHVRGEBDLKHLRAAWGKVPKDLIVMLRDTQVNNKKQKRTALHLA 180  
DB 121 gdydssafmepryhvrgebdldkhlraawgkvpkdlivmlrtdvnnkkdkrtalhl 180  
QY 181 SANGNSEVVKLLDRRCOLNVLDNKRKTALIKAVQCEDECALMLEHGTDPNIPDEYN 240  
DB 181 sangnsevvkllldrrcqlnvldnkrktalikavqcqededcalmlehgtdpnipdeygn 240  
QY 241 TTLHYAIYNEDKIMAKALLYGADIESKNKHGLTPLLGVHEQKQOVVFKLIKKAHLNA 300  
DB 241 ttlhyaiynedkimakalliygadiesknkhgltplllgvheqgqvkvflikkahlna 300  
QY 301 LDYRGRTALILAVCCGSASIVSLLEQNIIDVSSQDLSGQTAREYAVSSHHRVICQLLSY 360  
DB 301 ldrygrtalilavccgsasivslilleqnidvssqdlsgqtareyavsshhrvicqlilsdy 360  
QY 361 KEKOMLKISSENSNPE 376  
DB 361 kekqmlkissensnpe 376

RESULT 9  
ID AAY82018 standard; Protein; 656 AA.  
XX AAY82018;  
XX AAY82018;  
DT 13-JUN-2000 (first entry)  
XX Human immunogenic prostate tumour protein sequence SEQ ID NO:379.  
XX Human; prostate cancer; diagnosis; tumour; gene therapy; detection;  
XX immunogenic; cytostatic; vaccine.  
XX Homo sapiens.  
XX WO2000004149-A2.  
XX 27-JAN-2000.  
XX 14-JUL-1999; 99WO-US15838.  
XX 14-JUL-1998; 98US-0115453.  
XX 14-JUL-1998; 98US-0116134.  
XX 23-SEP-1998; 98US-0159812.  
XX 23-SEP-1998; 98US-0159822.  
XX 15-JAN-1999; 99US-0232149.  
XX 15-JAN-1999; 99US-0232880.  
XX 09-APR-1999; 99US-0288946.  
XX (CORI-) CORIXA CORP.  
XX Dillon DC, Harlocker SL, Yuqiu J, Xu J, Mitcham JL;  
XX WPI: 2000-171268/15.  
XX New polypeptide useful for treating and diagnosing prostate cancer  
XX comprises an immunogenic portion of prostate tumor protein -  
XX Disclosure; Page 229-231; 263pp; English.

XX The present invention describes isolated polypeptides, comprising an  
XX immunogenic portion of a prostate tumour protein (ptp). The polypeptides  
XX and polynucleotides encoding them have cytostatic activity and can be  
XX used in vaccines and in gene therapy. The polypeptides and  
XX polynucleotides encoding them, antigen presenting cells which express  
XX the polypeptides, antibodies against the polypeptides and vaccines  
XX comprising them can be used for inhibiting the development of prostate  
XX cancer in a patient. The polypeptides can be used to generate antibodies  
XX or anti-idiotypic antibodies for passive immuno therapy. A portion of  
XX the polynucleotides encoding the polypeptides can be used as a probe or  
XX to modulate the expression of the polypeptides. AAA06241 to AAA06691 and  
XX AAY82000 to AAY82020 represent sequences used in the exemplification of



XX 27-MAR-2001; 2001WO-US09919.  
PF  
XX 27-MAR-2000; 2000US-0536857.  
PR 09-MAY-2000; 2000US-0568100.  
PR 12-MAY-2000; 2000US-0570737.  
PR 13-JUN-2000; 2000US-0593793.  
PR 27-JUN-2000; 2000US-0605783.  
PR 10-AUG-2000; 2000US-0636215.  
PR 29-AUG-2000; 2000US-0651236.  
PR 06-SEP-2000; 2000US-0657279.  
PR 02-OCT-2000; 2000US-0679426.  
PR 10-OCT-2000; 2000US-0685166.  
XX (CORI-) CORIXA CORP.  
XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;  
PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedvick TS, Carter D;  
PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;  
XX WPI: 2001-639232/73.  
DR N-PSDB; AAS63808.  
XX New human prostate-specific polypeptides and polynucleotides useful for  
PT the diagnosis and treatment of cancer, especially prostate cancer -  
XX Claim 2: Page 356-357; 579pp; English.  
XX The invention relates to isolated prostate-specific  
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,  
CC antibodies raised against the polypeptides (or antigenic epitopes  
CC derived from them) and antigen-presenting cells expressing the  
CC polypeptides. The antibodies are useful for detecting the presence of  
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and  
CC the antigen-presenting cells are useful for stimulating and/or expanding  
CC T cells specific for a tumour protein, and for inhibiting the development  
CC of cancer especially prostate cancer. Compositions comprising the  
CC polynucleotide and/or polypeptide are useful for stimulating an immune  
CC response, and for treating cancer. The oligonucleotide is useful for  
CC detecting cancer. The present sequence is a prostate specific  
CC polypeptide of the invention.  
XX Sequence 656 AA;  
SQ  
Query Match 98.1%; Score 2024; DB 22; Length 656;  
Best Local Similarity 100.0%; Pred. No. 3.7e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MYVEVDSMPAASSVKKPGFLRSKMGKWCRCFPCCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvvevdsmpaassvkkpgflrskmgkwcrcfpccresgksnvgtsgdhdssamktrsk 60  
QY 61 MGKWCRCFPCCRGSGKSNVGASGDHDDSDAMKTLRNKMGKWCCHCFPCCRGSGSKSVGAW 120  
Db 61 mgkwrcrchfpcrcrgsgksnvgasgdhddsdamktrlnkmgkwccchcfpcrcrgsgsksvgaw 120  
QY 121 GDYDDSAFMEPRYHVRGSDLOKLRAAWGWKVPKDLIVMLRDTDVNKKDKOKRTALHLA 180  
Db 121 gdyddsafmepryhvrgeidoklrraawgwkvprkdlivmlrtdtdvnkkdkokrtalhla 180  
QY 181 SANGNSEVVKLLIDRRCOLVLDNKKRTALIKAVQCQDEECALMLLEHGTDPNTPDEYGN 240  
Db 181 sangnsevvkllidrrcolvldnkkrtalikaqcqdeecalmllhgtdpnptdeygn 240  
QY 241 TTLHYAIYNEDKLMKAKALLYGADIESKNKHGLTPLLGVHEQKQVQVYKFLIKKKANLNA 300  
Db 241 ttlhyaiynedklmakalllygadiesknkhgltptllgvheqkqvvykflkkkanlna 300  
QY 301 LDYRGRTALILAVCCGSASIVSLLEQNIIDVSSODLSGGTAREYAVSSHHRVICQLSDY 360  
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsggtareyavsshhrvicqlisd y 360

QY 361 KEQOMLKISSNSNPE 376  
Db 361 kekqmlkissensnpe 376  
RESULT 12  
AAM01133  
ID AAM01133 standard; Protein; 656 AA.  
XX AAM01133;  
XX AC AAM01133;  
XX DT 04-OCT-2001 (first entry)  
XX DE Human prostate-specific sequence B305D amino acid splice variant #14.  
XX KW Human prostate cancer; prostate-specific; diagnosis; vaccine;  
XX OS cytostatic; gene therapy; metastasis.  
XX OS Homo sapiens.  
XX PN WO200151633-A2.  
XX PD 19-JUL-2001.  
XX PF 16-JAN-2001; 2001WO-US01574.  
XX PR 14-JAN-2000; 2000US-0483672.  
XX (CORI-) CORIXA CORP.  
XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;  
PI Kalos MD, Fanger GR, Day CH, Retter MW, Stolk JA, Skeiky YAW;  
PI Wang A, Meagher MJ;  
XX WPI: 2001-425873/45.  
XX New polynucleotide encoding a prostate-specific protein, for  
PT diagnosing, monitoring and treating prostate cancer in a patient and  
PT for use in vaccines -  
XX Claim 2: Page 354-355; 543pp; English.  
XX The present invention describes polynucleotide sequences (I) which encode  
CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,  
CC and can be used in vaccine production and gene therapy. (I), (II),  
CC antibodies to (II), fusion proteins comprising (II), and isolated  
CC T cells prepared using (I) or (II) are used treat cancer in a patient.  
CC (I) and the antibodies are also used in the detection of cancer in a  
CC patient. The cancer that is diagnosed or treated is particularly  
CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or  
CC (I) can be used for monitoring the progression of cancer in a patient.  
CC (I) and (II) can also be used to improve diagnostic and therapeutic  
CC methods for prostate cancer. They can indicate the level of metastasis  
CC as well as the prostate volume. AAR93357 to AAR93944 and AAM01115 to  
CC AAM01318 represent polynucleotide and amino acid sequences used in the  
CC exemplification of the present invention.  
XX Sequence 656 AA;  
SQ  
Query Match 98.1%; Score 2024; DB 22; Length 656;  
Best Local Similarity 100.0%; Pred. No. 3.7e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MYVEVDSMPAASSVKKPGFLRSKMGKWCRCFPCCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvvevdsmpaassvkkpgflrskmgkwcrcfpccresgksnvgtsgdhdssamktrsk 60  
QY 61 MGKWCRCFPCCRGSGKSNVGASGDHDDSDAMKTLRNKMGKWCCHCFPCCRGSGSKSVGAW 120  
Db 61 mgkwrcrchfpcrcrgsgksnvgasgdhddsdamktrlnkmgkwccchcfpcrcrgsksvgaw 120  
QY 121 GDYDDSAFMEPRYHVRGSDLOKLRAAWGWKVPKDLIVMLRDTDVNKKDKOKRTALHLA 180



Db 121 gyyddsaefmepzyhvrgeidklhraawgkvrkdliwmlrtdvnnkdkqkrtalhla 180  
QY 181 SANGSEVVKLLDRRCQLNVLDNKKRTALIKAVQCQDECALMLEHGTDPNPDEYGN 240  
Db 181 sangsevvkllldrrcqlnvldnkkrtalikaavqcqdecalmlehgtdpnpdeygn 240  
QY 241 TTLHYAIYNEDKLMAKALLYGADIESKNKHGUTPLLLGVHQBKQOVVVKFLIKKANLNA 300  
Db 241 ttlihyaiynedklmakalllygadiesknkhgltplllgvheqkgvkvkflikkkanlna 300  
QY 301 LDYGRRTALILAVCCGSASIVSLLLEONIDVSSQDLSGQTAREYAVSSHVHVICQLLSY 360  
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgqtareyavsshvhvicqllsdy 360  
QY 361 KEQOMLKISSENSNPE 376  
Db 361 kekqmlkissensnpe 376  
RESULT 13  
AAG99018  
ID AAG99018 standard; Protein; 656 AA.  
XX AC AAG99018;  
XX DT 25-SEP-2001 (first entry)  
XX DE Human prostate-specific amino acid sequence B305D splice variant #4.  
XX KW Human: prostate cancer; therapy; diagnosis; cat eye syndrome;  
KW chromosome 22q11.2; prostate-specific protein; chromosome 1;  
KW prostate specific antigen; PSA.  
XX OS Homo sapiens.  
XX PN WO200134802-A2.  
XX PD 17-MAY-2001.  
XX PF 09-NOV-2000; 2000WO-US30904.  
XX PR 12-NOV-1999; 99US-0439313.  
XX PR 18-NOV-1999; 99US-0443686.  
XX PA (CORI-) CORIXA CORP.  
XX PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;  
PI Kalos MD, Retter MW, Stolk JA, Day CH, Skeiky YAW, Wang A;  
XX DR WPI; 2001-308785/32.  
XX Isolated polypeptide comprising at least an immunogenic portion of a  
PT prostate-specific protein, useful in the diagnosis and therapy of  
PT prostate cancer -  
XX PS Disclosure; Page 254-255; 325pp; English.  
XX CC The present invention describes an isolated polypeptide (P1) comprising  
CC at least an immunogenic portion of a prostate-specific protein, or its  
CC variant. Also described are polynucleotides (N1) encoding (P1). (P1) and  
CC (N1) have cytostatic activity and can be used in vaccine production.  
CC The polypeptides, nucleic acids and antibodies from the present  
CC invention are useful in the diagnosis and therapy of prostate cancer.  
CC Prostate specific genes p704P, p712P, p774P, p775P and B305D are located  
CC in a genomic region on chromosome 22q11.2 known as the Cat Eye syndrome  
CC region. Prostate specific antigen (PSA) p501S was located on  
CC chromosome 1. AAH84671 to AAH85143 and AAG99000 to AAG99077 represent  
CC of the present invention.  
XX Sequence 656 AA;

Query Match 98.1%; Score 2024; DB 22; Length 656;  
Best Local Similarity 100.0%; Pred. No. 3.7e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MVVEVDSMPAASSVKKPFGLRSKMGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvvevdmpaassvkkpfglrskmgkwccrcfpcrcresgksnvgtsgdhdssamktlrsk 60  
QY 61 MGKWCRCFCPCRCGSGKSNVGASGDHDDSAMKTLRNKMGKWCCHCFCPCRCGSGKSKVGAW 120  
Db 61 mgkwcrhcfpcrcrgsgksnvgasgdhddsamktlrnkmgkwccchcfpcrcrgsgkskvaw 120  
QY 121 GOYDSDAFMPEPRYHVRGEDLDKLHRAAWGKVPKRDLIWMLRDTDVNNKKQKRTALHLA 180  
Db 121 gdydssafmepryhvrgeidklhraawgkvrkdliwmlrtdvnnkkqkrtalhla 180  
QY 181 SANGSEVVKLLDRRCQLNVLDNKKRTALIKAVQCQDECALMLEHGTDPNPDEYGN 240  
Db 181 sangsevvkllldrrcqlnvldnkkrtalikaavqcqdecalmlehgtdpnpdeygn 240  
QY 241 TTLHYAIYNEDKLMAKALLYGADIESKNKHGUTPLLLGVHQBKQOVVVKFLIKKANLNA 300  
Db 241 ttlihyaiynedklmakalllygadiesknkhgltplllgvheqkgvkvkflikkkanlna 300  
QY 301 LDYGRRTALILAVCCGSASIVSLLLEQNTIDVSSQDLSGQTAREYAVSSHVHVICQLLSY 360  
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgqtareyavsshvhvicqllsdy 360  
QY 361 KEQOMLKISSENSNPE 376  
Db 361 kekqmlkissensnpe 376  
RESULT 14  
AAB74816  
ID AAB74816 standard; Protein; 656 AA.  
XX AC AAB74816;  
XX DT 14-JUN-2001 (first entry)  
XX DE Prostate tumour antigen splice variant of B305D amino acid sequence #4.  
XX KW Human: prostate tumour antigen; prostate cancer; diagnosis;  
KW prostate cancer; immunogenic; cytostatic; vaccine.  
XX OS Homo sapiens.  
XX PN WO200125272-A2.  
XX PD 12-APR-2001.  
XX PF 04-OCT-2000; 2000WO-US27464.  
XX PR 04-OCT-1999; 99US-0157455.  
XX PA (CORI-) CORIXA CORP.  
XX PI Xu J, Skeiky YAW, Reed SG, Cheever MA;  
XX DR WPI; 2001-245062/25.  
XX N-PSDB; AAH02780.  
XX PT Prostate specific protein and its encoding polynucleotide, useful for  
PT the treatment and diagnosis of prostate cancer -  
XX PS Disclosure; Page 238-239; 276pp; English.  
XX CC The present invention describes an isolated polypeptide (I) comprising  
CC at least an immunogenic portion of a prostate tumour antigen protein or  
CC its variant. (I) have cytostatic activity and can be used in vaccine  
CC production. (I), prostate tumour antigen polynucleotides, an antigen  
CC

CC presenting cell (APC e.g. a dendritic cell) that expresses (I), and a  
CC pharmaceutical composition containing (I) are useful for inhibiting the  
CC development of cancer in a patient. Antibodies specific for prostate  
CC specific proteins and oligonucleotides that hybridize to a  
CC polynucleotide that encodes a prostate specific protein are useful  
CC for detecting the presence or absence of a cancer or monitoring the  
CC progression the progression of a cancer, especially prostate cancer.  
CC AA02422 to AA2872, AA874798 to AA874821 and AA874830 are sequences  
CC used in the exemplification of the present invention.  
XX  
XX  
SQ Sequence 656 AA;

Query Match 98.1%; Score 2024; DB 22; Length 656;  
Best Local Similarity 100.0%; Pred. No. 3.7e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MVEVDSMPAASVKKPFGLRSKMGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvvevdempaassvkkpfglrskmgkwcrcfpcrcresgksnvgtsgdhdssamktlrsk 60  
Qy 61 MGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRNKMGKWCRCPCPCRESGSKSVGAW 120  
Db 61 mgkwcrcfpcrcresgksnvgtsgdhdssamktlrnmgkwcrcfpcrcresgkskvagaw 120  
Qy 121 GDYDSSAFMEPRYHVRGEDIKLRHAAWGWKVPKRDILVMLRDTVNKKDKQKRTALHLA 180  
Db 121 gdydssafmepryhvrgeidklhraawgwkrkolivmlrtdvnnkdkqkrtalhla 180  
Qy 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCQDECALMLEHGTDPNIPDEYGN 240  
Db 181 sangnsevvkllldrrcqnlvldnkkrtalikavqcqdecalmlehgtdpnpideygn 240  
Qy 241 TTLHYAIYNEDKLMKALLYGADIESKNKHGTLPLLGVHEQKQOVVVKFLIKKANLNA 300  
Db 241 ttlyhaiynedklmakallygadiesknkhgltplllgvheqkgqvkvflikkkanlna 300  
Qy 301 LDYGRGTALILAVCCGSASIVSLLEQNTIDVSSQDLSGQTAREYAVSSHVVICQLLSY 360  
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgqtareyavsshvhhvicqlilsdy 360  
Qy 361 KEKQMLKISSNSNPE 376  
Db 361 kekqmlkissensnpe 376

RESULT 15  
AAB28630  
ID AAB28630 standard; Protein; 671 AA.  
XX  
AC AAB28630;  
XX  
DT 13-FEB-2001 (first entry)  
XX  
DE Human B1Agl antigen splice isoform B1IC-9-16.  
XX  
KW Human; breast tumour-specific antigen; cytostatic; vaccine;  
KW breast cancer; B18Agl; B1Agl; B15Agl.  
XX  
OS Homo sapiens.  
XX  
PN WO2000061753-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 07-APR-2000; 2000WO-US09312.  
XX  
PR 09-APR-1999; 99US-0289198.  
PR 28-OCT-1999; 99US-0429755.  
PR 23-MAR-2000; 2000US-0534825.  
XX  
PA (CORI-) CORIXA CORP.  
XX

PI Frudakis TN, Smith JM, Reed SG, Misher LE, Retter MW, Dillon DC;  
XX WPI; 2000-628403/60.  
DR N-PSDB; AAC81013.  
XX  
PT An isolated polypeptide comprising an immunogenic portion of a breast  
PT tumor protein used for inhibiting the development of cancer, especially  
PT breast cancer, and monitoring cancer progression in a patient -  
XX  
XX Claim 3; Page 181-183; 187pp; English.

CC The present sequence is given in a specification relating to compositions  
CC and methods for the treatment and diagnosis of breast cancer. Nucleotide  
CC sequences that are preferentially expressed in breast tumour tissue, and  
CC the polypeptides encoded by such nucleotide sequences, are used in  
CC especially breast cancer. The progression of a cancer may be monitored by  
CC carrying out detection of tumour-specific antigens at subsequent time  
CC points and comparing the results from the different time points. The  
CC CD4+ and/or CD8+ T-cells isolated from the cancer patient may be treated  
CC with tumour-specific polypeptides, polynucleotides encoding the  
CC polypeptides or antigen presenting cells expressing the polypeptides. The  
CC cells are then administered to the patient to inhibit development of  
CC cancer.

XX Sequence 671 AA;

Query Match 98.1%; Score 2024; DB 21; Length 671;  
Best Local Similarity 100.0%; Pred. No. 3.9e-189;  
Matches 376; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MVEVDSMPAASVKKPFGLRSKMGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRSK 60  
Db 1 mvvevdempaassvkkpfglrskmgkwcrcfpcrcresgksnvgtsgdhdssamktlrsk 60  
Qy 61 MGKWCRCPCPCRESGKSNVGTSGDHDSDAMKTLRNKMGKWCRCPCPCRESGSKSVGAW 120  
Db 61 mgkwcrcfpcrcresgksnvgtsgdhdssamktlrnmgkwcrcfpcrcresgkskvagaw 120  
Qy 121 GDYDSSAFMEPRYHVRGEDIKLRHAAWGWKVPKRDILVMLRDTVNKKDKQKRTALHLA 180  
Db 121 gdydssafmepryhvrgeidklhraawgwkrkolivmlrtdvnnkdkqkrtalhla 180  
Qy 181 SANGNSEVVKLLDRRCQLNVLDNKKRTALIKAVQCQDECALMLEHGTDPNIPDEYGN 240  
Db 181 sangnsevvkllldrrcqnlvldnkkrtalikavqcqdecalmlehgtdpnpideygn 240  
Qy 241 TTLHYAIYNEDKLMKALLYGADIESKNKHGTLPLLGVHEQKQOVVVKFLIKKANLNA 300  
Db 241 ttlyhaiynedklmakallygadiesknkhgltplllgvheqkgqvkvflikkkanlna 300  
Qy 301 LDYGRGTALILAVCCGSASIVSLLEQNTIDVSSQDLSGQTAREYAVSSHVVICQLLSY 360  
Db 301 ldrygrtalilavccgsasivslleqnidvssqdlsgqtareyavsshvhhvicqlilsdy 360  
Qy 361 KEKQMLKISSNSNPE 376  
Db 361 kekqmlkissensnpe 376

Search completed: August 28, 2002, 11:29:12  
Job time: 540 sec